

Table 1.108A Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 or Older; Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	18,290	<i>18,332</i>	4,929	<i>5,092</i>	4,929	<i>5,092</i>
Amphetamine or Methylphenidate Products	14,294	<i>13,863</i>	4,711	<i>4,699</i>	4,711	<i>4,699</i>
Amphetamine Products	12,647	<i>11,853</i>	4,486	<i>4,435</i>	4,486	<i>4,435</i>
Methylphenidate Products	3,383	<i>3,812</i>	704	<i>661</i>	704	<i>661</i>
Anorectic (Weight-Loss) Stimulants	2,220	<i>2,790</i>	207	<i>231</i>	207	<i>231</i>
Provigil®	536	<i>536</i>	87	<i>119</i>	*	*
Any Other Prescription Stimulant ¹	2,594	<i>2,763</i>	31	<i>97</i>	31	<i>97</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.108B Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 or Older; Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	6.6	6.6	1.8	1.8	26.9	27.8
Amphetamine or Methylphenidate Products	5.2	5.0	1.7	1.7	33.0	33.9
Amphetamine Products	4.6	4.3	1.6	1.6	35.5	37.4
Methylphenidate Products	1.2	1.4	0.3	0.2	20.8	17.3
Anorectic (Weight-Loss) Stimulants	0.8	1.0	0.1	0.1	9.3	8.3
Provigil®	0.2	0.2	0.0	0.0	*	*
Any Other Prescription Stimulant ¹	0.9	1.0	0.0	0.0	1.2	3.5

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.109A Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 to 17; Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	1,837	<i>1,593</i>	430	288	430	288
Amphetamine or Methylphenidate Products	1,643	<i>1,409</i>	407	253	407	253
Amphetamine Products	1,301	<i>964</i>	373	235	373	235
Methylphenidate Products	590	<i>625</i>	80	61	80	61
Anorectic (Weight-Loss) Stimulants	72	<i>32</i>	15	5	*	*
Provigil®	9	<i>12</i>	2	*	*	*
Any Other Prescription Stimulant ¹	360	<i>272</i>	17	22	17	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.109B Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 12 to 17; Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
ANY PRESCRIPTION STIMULANT	7.4	<i>6.4</i>	1.7	<i>1.2</i>	23.4	<i>18.1</i>
Amphetamine or Methylphenidate Products	6.6	<i>5.6</i>	1.6	<i>1.0</i>	24.8	<i>18.0</i>
Amphetamine Products	5.2	<i>3.9</i>	1.5	<i>0.9</i>	28.6	<i>24.3</i>
Methylphenidate Products	2.4	<i>2.5</i>	0.3	<i>0.2</i>	13.6	<i>9.8</i>
Anorectic (Weight-Loss) Stimulants	0.3	<i>0.1</i>	0.1	<i>0.0</i>	*	*
Provigil®	0.0	<i>0.0</i>	0.0	*	*	*
Any Other Prescription Stimulant ¹	1.4	<i>1.1</i>	0.1	<i>0.1</i>	4.7	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.110A Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 or Older; Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	16,453	<i>16,739</i>	4,499	<i>4,804</i>	4,499	<i>4,804</i>
Amphetamine or Methylphenidate Products	12,650	<i>12,454</i>	4,304	<i>4,446</i>	4,304	<i>4,446</i>
Amphetamine Products	11,346	<i>10,890</i>	4,114	<i>4,200</i>	4,114	<i>4,200</i>
Methylphenidate Products	2,792	<i>3,187</i>	623	<i>600</i>	623	<i>600</i>
Anorectic (Weight-Loss) Stimulants	2,148	<i>2,758</i>	193	<i>226</i>	193	<i>226</i>
Provigil®	527	<i>524</i>	85	<i>119</i>	*	*
Any Other Prescription Stimulant ¹	2,235	<i>2,491</i>	14	<i>76</i>	14	<i>76</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.110B Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 or Older; Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	6.6	6.6	1.8	1.9	27.3	28.7
Amphetamine or Methylphenidate Products	5.1	4.9	1.7	1.8	34.0	35.7
Amphetamine Products	4.5	4.3	1.6	1.7	36.3	38.6
Methylphenidate Products	1.1	1.3	0.2	0.2	22.3	18.8
Anorectic (Weight-Loss) Stimulants	0.9	1.1	0.1	0.1	9.0	8.2
Provigil®	0.2	0.2	0.0	0.0	*	*
Any Other Prescription Stimulant ¹	0.9	1.0	0.0	0.0	0.6	3.0

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.111A Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 to 25; Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	4,320	3,773	1,951	<i>1,616</i>	1,951	<i>1,616</i>
Amphetamine or Methylphenidate Products	3,998	3,536	1,926	<i>1,603</i>	1,926	<i>1,603</i>
Amphetamine Products	3,615	3,168	1,845	<i>1,529</i>	1,845	<i>1,529</i>
Methylphenidate Products	1,011	887	300	<i>216</i>	300	<i>216</i>
Anorectic (Weight-Loss) Stimulants	189	<i>192</i>	27	<i>19</i>	*	*
Provigil®	47	<i>21</i>	10	<i>6</i>	*	*
Any Other Prescription Stimulant ¹	361	<i>247</i>	14	<i>15</i>	14	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.111B Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 18 to 25; Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	12.8	<i>11.3</i>	5.8	<i>4.8</i>	45.2	<i>42.8</i>
Amphetamine or Methylphenidate Products	11.9	<i>10.6</i>	5.7	<i>4.8</i>	48.2	<i>45.3</i>
Amphetamine Products	10.7	<i>9.5</i>	5.5	<i>4.6</i>	51.0	<i>48.3</i>
Methylphenidate Products	3.0	<i>2.6</i>	0.9	<i>0.6</i>	29.7	<i>24.4</i>
Anorectic (Weight-Loss) Stimulants	0.6	<i>0.6</i>	0.1	<i>0.1</i>	*	*
Provigil®	0.1	<i>0.1</i>	0.0	<i>0.0</i>	*	*
Any Other Prescription Stimulant ¹	1.1	<i>0.7</i>	0.0	<i>0.0</i>	4.0	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.112A Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 26 or Older; Numbers in Thousands, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Stimulant Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION STIMULANT	12,133	<i>12,966</i>	2,548	<i>3,188</i>	2,548	<i>3,188</i>
Amphetamine or Methylphenidate Products	8,652	<i>8,918</i>	2,378	<i>2,843</i>	2,378	<i>2,843</i>
Amphetamine Products	7,732	<i>7,721</i>	2,269	<i>2,671</i>	2,269	<i>2,671</i>
Methylphenidate Products	1,781	<i>2,300</i>	323	<i>383</i>	323	<i>383</i>
Anorectic (Weight-Loss) Stimulants	1,959	<i>2,566</i>	165	<i>207</i>	165	<i>207</i>
Provigil®	480	<i>503</i>	76	<i>113</i>	*	*
Any Other Prescription Stimulant ¹	1,874	<i>2,244</i>	*	<i>60</i>	*	<i>60</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.112B Any Use and Misuse of Prescription Stimulant Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Stimulant Subtypes in Past Year: Among Past Year Any Users of Prescription Stimulant Subtypes Aged 26 or Older; Percentages, 2019 and 2020

Stimulant Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Stimulant Subtypes (2019)	in Past Year among Any Users of Stimulant Subtypes (2020)
ANY PRESCRIPTION STIMULANT	5.6	5.9	1.2	1.5	21.0	24.6
Amphetamine or Methylphenidate Products	4.0	4.1	1.1	1.3	27.5	31.9
Amphetamine Products	3.6	3.5	1.0	1.2	29.3	34.6
Methylphenidate Products	0.8	1.1	0.1	0.2	18.1	16.7
Anorectic (Weight-Loss) Stimulants	0.9	1.2	0.1	0.1	8.4	8.1
Provigil®	0.2	0.2	0.0	0.1	*	*
Any Other Prescription Stimulant ¹	0.9	1.0	*	0.0	*	2.7

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of “any other prescription stimulant” that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.